Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

25 results

Filters applied: . Clear all
Page 1
Modulation, microbiota and inflammation in the adult CF gut: A prospective study.
Ronan NJ, Einarsson GG, Deane J, Fouhy F, Rea M, Hill C, Shanahan F, Elborn JS, Ross RP, McCarthy M, Murphy DM, Eustace JA, Mm T, Stanton C, Plant BJ. Ronan NJ, et al. Among authors: elborn js. J Cyst Fibros. 2022 Sep;21(5):837-843. doi: 10.1016/j.jcf.2022.06.002. Epub 2022 Jun 25. J Cyst Fibros. 2022. PMID: 35764510 Free article.
In this adult cohort, exocrine pancreatic function was irreversibly lost. Longer term follow-up may reveal more dynamic changes in the gut microbiota and possible restoration of CFTR function....
In this adult cohort, exocrine pancreatic function was irreversibly lost. Longer term follow-up may reveal more dynamic changes in th …
Bronchiectasis and inhaled tobramycin: A literature review.
Elborn JS, Blasi F, Haworth CS, Ballmann M, Tiddens HAWM, Murris-Espin M, Chalmers JD, Cantin AM. Elborn JS, et al. Respir Med. 2022 Feb;192:106728. doi: 10.1016/j.rmed.2021.106728. Epub 2022 Jan 1. Respir Med. 2022. PMID: 34998112 Free article. Review.
Definitive phase 3 trials of inhaled tobramycin in patients with bronchiectasis are indicated to determine clinical efficacy and long-term safety....
Definitive phase 3 trials of inhaled tobramycin in patients with bronchiectasis are indicated to determine clinical efficacy and long-ter …
Management of chronic Pseudomonas aeruginosa infection with inhaled levofloxacin in people with cystic fibrosis.
Elborn JS, Flume PA, Van Devanter DR, Procaccianti C. Elborn JS, et al. Future Microbiol. 2021 Sep;16:1087-1104. doi: 10.2217/fmb-2021-0150. Epub 2021 Aug 13. Future Microbiol. 2021. PMID: 34384254 Free article. Review.
By adulthood, chronic Pseudomonas aeruginosa (Pa) is the most prevalent infective organism and is difficult to eradicate owing to its adaptation to the CF lung microenvironment. Long-term suppressive treatment with inhaled antimicrobials is the standard care for reducing e …
By adulthood, chronic Pseudomonas aeruginosa (Pa) is the most prevalent infective organism and is difficult to eradicate owing to its adapta …
Psychometrics of health-related quality of life questionnaires in bronchiectasis: a systematic review and meta-analysis.
McLeese RH, Spinou A, Alfahl Z, Tsagris M, Elborn JS, Chalmers JD, De Soyza A, Loebinger MR, Birring SS, Fragkos KC, Wilson R, O'Neill K, Bradley JM. McLeese RH, et al. Among authors: elborn js. Eur Respir J. 2021 Nov 11;58(5):2100025. doi: 10.1183/13993003.00025-2021. Print 2021 Nov. Eur Respir J. 2021. PMID: 33888521 Free PMC article.
CONCLUSIONS: SGRQ was the most widely used HRQoL questionnaire in bronchiectasis studies and it had good psychometric properties; however, good psychometric data are emerging on the bronchiectasis-specific HRQoL questionnaires QOL-B and BHQ. Future studies should focus on the med …
CONCLUSIONS: SGRQ was the most widely used HRQoL questionnaire in bronchiectasis studies and it had good psychometric properties; however, g …
Neutrophil extracellular traps, disease severity, and antibiotic response in bronchiectasis: an international, observational, multicohort study.
Keir HR, Shoemark A, Dicker AJ, Perea L, Pollock J, Giam YH, Suarez-Cuartin G, Crichton ML, Lonergan M, Oriano M, Cant E, Einarsson GG, Furrie E, Elborn JS, Fong CJ, Finch S, Rogers GB, Blasi F, Sibila O, Aliberti S, Simpson JL, Huang JTJ, Chalmers JD. Keir HR, et al. Among authors: elborn js. Lancet Respir Med. 2021 Aug;9(8):873-884. doi: 10.1016/S2213-2600(20)30504-X. Epub 2021 Feb 17. Lancet Respir Med. 2021. PMID: 33609487
Fourth, to assess the potential use of macrolides to reduce NETs in patients with bronchiectasis, we examined two studies of long-term macrolide treatment, one in patients with bronchiectasis (n=52 from the UK) in which patients were given 250 mg of azithromycin three time …
Fourth, to assess the potential use of macrolides to reduce NETs in patients with bronchiectasis, we examined two studies of long-term …
Bronchiectasis: Treatment decisions for pulmonary exacerbations and their prevention.
Bell SC, Elborn JS, Byrnes CA. Bell SC, et al. Among authors: elborn js. Respirology. 2018 Nov;23(11):1006-1022. doi: 10.1111/resp.13398. Epub 2018 Sep 11. Respirology. 2018. PMID: 30207018 Free article. Review.
This review considers the evidence for defining and treating pulmonary exacerbations, the approaches for eradication of newly identified airway pathogens and the methods to prevent exacerbations through long-term treatments from a pragmatic practice-based perspective. Area …
This review considers the evidence for defining and treating pulmonary exacerbations, the approaches for eradication of newly identified air …
Ciprofloxacin Dry Powder for Inhalation (ciprofloxacin DPI): Technical design and features of an efficient drug-device combination.
McShane PJ, Weers JG, Tarara TE, Haynes A, Durbha P, Miller DP, Mundry T, Operschall E, Elborn JS. McShane PJ, et al. Among authors: elborn js. Pulm Pharmacol Ther. 2018 Jun;50:72-79. doi: 10.1016/j.pupt.2018.03.005. Epub 2018 Apr 3. Pulm Pharmacol Ther. 2018. PMID: 29621625 Free article. Review.
However, there are no approved therapies to reduce or delay exacerbations in this patient population. Ciprofloxacin DPI is in development as a long-term, intermittent therapy to reduce exacerbations in patients with non-cystic fibrosis (CF) bronchiectasis and evidence of r …
However, there are no approved therapies to reduce or delay exacerbations in this patient population. Ciprofloxacin DPI is in development as …
The RESPIRE trials: Two phase III, randomized, multicentre, placebo-controlled trials of Ciprofloxacin Dry Powder for Inhalation (Ciprofloxacin DPI) in non-cystic fibrosis bronchiectasis.
Aksamit T, Bandel TJ, Criollo M, De Soyza A, Elborn JS, Operschall E, Polverino E, Roth K, Winthrop KL, Wilson R. Aksamit T, et al. Among authors: elborn js. Contemp Clin Trials. 2017 Jul;58:78-85. doi: 10.1016/j.cct.2017.05.007. Epub 2017 May 8. Contemp Clin Trials. 2017. PMID: 28495619 Free article. Clinical Trial.
The primary goals of long-term disease management in non-cystic fibrosis bronchiectasis (NCFB) are to reduce the number of exacerbations, and improve quality of life. ...Ciprofloxacin Dry Powder for Inhalation (Ciprofloxacin DPI) has potential to be the first long-term …
The primary goals of long-term disease management in non-cystic fibrosis bronchiectasis (NCFB) are to reduce the number of exacerbati …
Current strategies for the long-term assessment, monitoring, and management of cystic fibrosis patients treated with CFTR modulator therapy.
Elborn JS, Davies J, Mall MA, Flume PA, Plant B. Elborn JS, et al. J Cyst Fibros. 2017 Jan;16(1):163-164. doi: 10.1016/j.jcf.2016.11.009. Epub 2016 Dec 13. J Cyst Fibros. 2017. PMID: 27986495 Free article.
The content for this activity is based on the satellite symposium, "Current Strategies for the Long-term Assessment, Monitoring, and Management for Cystic Fibrosis Patients Treated with CFTR Modulator Therapy" that was presented at the 39th European Cystic Fibrosis Society …
The content for this activity is based on the satellite symposium, "Current Strategies for the Long-term Assessment, Monitoring, and …
MRSA eradication of newly acquired lower respiratory tract infection in cystic fibrosis.
Vallières E, Rendall JC, Moore JE, McCaughan J, Hoeritzauer AI, Tunney MM, Elborn JS, Downey DG. Vallières E, et al. Among authors: elborn js. ERJ Open Res. 2016 Mar 15;2(1):00064-2015. doi: 10.1183/23120541.00064-2015. eCollection 2016 Jan. ERJ Open Res. 2016. PMID: 27730175 Free PMC article.
As there is no clear consensus as to which eradication regimen is most effective, we determined the efficacy of eradication regimens used in our CF centre and long-term clinical outcome. All new MRSA positive sputum cultures (n=37) that occurred between 2000 and 2014 were …
As there is no clear consensus as to which eradication regimen is most effective, we determined the efficacy of eradication regimens used in …
25 results